Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-3
Shelf registration
18 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
8-K
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
20 Mar 24
424B5
Prospectus supplement for primary offering
20 Mar 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
26 Feb 24
EFFECT
Notice of effectiveness
28 Nov 23
CORRESP
Correspondence with SEC
21 Nov 23
UPLOAD
Letter from SEC
15 Nov 23
8-K
Entry into a Material Definitive Agreement
8 Nov 23
S-3
Shelf registration
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
8 Nov 23
8-K
Other Events
1 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Departure of Directors or Certain Officers
8 Jun 23
8-K
Other Events
7 Jun 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
3 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
28 Feb 23
8-K
Termination of a Material Definitive Agreement
5 Jan 23
8-K
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
7 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
3 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
3 Aug 22
8-K
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration
30 Jun 22
8-K
Departure of Directors or Certain Officers
13 Jun 22
S-8
Registration of securities for employees
9 Jun 22
10-Q
2022 Q1
Quarterly report
4 May 22
Latest ownership filings
4
Jeremy Green
25 Mar 24
SC 13D/A
Redmile Group, LLC
25 Mar 24
4
Edward J Dulac III
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
Boxer Capital, LLC
12 Feb 24
SC 13G/A
Capital World Investors
9 Feb 24
4
J Scott Wolchko
2 Feb 24
4
CINDY TAHL
2 Feb 24
4
Edward J Dulac III
2 Feb 24
4
Bahram Valamehr
2 Feb 24
4
Edward J Dulac III
30 Jan 24
144
Notice of proposed sale of securities
29 Jan 24
SC 13G
Point72 Asset Management, L.P.
25 Jan 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
4
CINDY TAHL
10 Jan 24
4
Bahram Valamehr
10 Jan 24
4
J Scott Wolchko
10 Jan 24
4
Edward J Dulac III
10 Jan 24
144
Notice of proposed sale of securities
9 Jan 24
144
Notice of proposed sale of securities
9 Jan 24
144
Notice of proposed sale of securities
9 Jan 24
144
Notice of proposed sale of securities
9 Jan 24
4
Edward J Dulac III
3 Jan 24
144
Notice of proposed sale of securities
2 Jan 24
4
Jeremy Green
28 Dec 23
SC 13D/A
Redmile Group, LLC
28 Dec 23
4
Edward J Dulac III
19 Dec 23
144
Notice of proposed sale of securities
18 Dec 23
4
CINDY TAHL
13 Nov 23
144
Notice of proposed sale of securities
9 Nov 23
SC 13G/A
STATE STREET CORP
10 Oct 23
4
Edward J Dulac III
21 Aug 23
144
Notice of proposed sale of securities
18 Aug 23
4
Yuan Xu
7 Aug 23
144
Notice of proposed sale of securities
4 Aug 23
4
Brian T. Powl
6 Jul 23
4
Edward J Dulac III
6 Jul 23
144
Notice of proposed sale of securities
5 Jul 23